We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+26.11%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$191M
AUM Growth
+$49.9M
Cap. Flow
+$34.4M
Cap. Flow %
17.96%
Top 10 Hldgs %
57.43%
Holding
46
New
18
Increased
5
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$12.5M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$12M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$10.6M
4
ALIM
Alimera Sciences
ALIM
+$9.71M
5
OFIX icon
Orthofix Medical
OFIX
+$5.76M

Top Sells

Rank Stock Value
1
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$8.78M
2
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$8.6M
3
AERI
Aerie Pharmaceuticals
AERI
+$5.54M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$5.21M
5
CYNO
Cynosure, Inc. Class A
CYNO
+$4.53M

Sector Composition

Rank Sector Weight
1 Healthcare 66.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FURX
1
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$17.9M 9.35%
205,858
-113,678
-36% -$8.78M
HPTX
2
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$12.7M 6.65%
493,751
-317,362
-39% -$8.6M
FLNA
3
Filana Therapeutics
FLNA
$48.8M
$12.6M 6.57%
326,754
-72,916
-18% -$2.57M
ALIM
4
DELISTED
Alimera Sciences
ALIM
$11.8M 6.18%
+100,000
New +$9.71M
DSCI
5
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$11.7M 6.13%
+925,000
New +$12M
TENX icon
6
Tenax Therapeutics
TENX
$363M
$11.1M 5.8%
+63
New +$12.5M
NBIX icon
7
Neurocrine Biosciences
NBIX
$16.8B
$9.98M 5.21%
+620,000
New +$10.6M
OFIX icon
8
PUT
Orthofix Medical
OFIX
$477M
$7.99M 4.17%
+265,000
New +$6.11M
OFIX icon
9
Orthofix Medical
OFIX
$477M
$7.54M 3.94%
+250,000
New +$5.76M
AMBI
10
DELISTED
Ambit Biosciences Corp
AMBI
$6.56M 3.43%
719,261
-13,339
-2% -$142K
INFI
11
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$5.95M 3.11%
500,400
+49,300
+11% +$662K
VOLC
12
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$5.91M 3.09%
300,000
+100,000
+50% +$2.14M
ARCT icon
13
Arcturus Therapeutics
ARCT
$164M
$5.33M 2.78%
41,944
+6,230
+17% +$923K
VCYT icon
14
Veracyte
VCYT
$3.7B
$5.32M 2.78%
310,248
-43,677
-12% -$698K
SPHS
15
DELISTED
Sophiris Bio, Inc.
SPHS
$5M 2.61%
1,500,000
+120,340
+9% +$471K
ANTH
16
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$4.59M 2.4%
+171,155
New +$4.35M
AVEO
17
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$4.29M 2.24%
286,648
-13,352
-4% -$240K
NUWE icon
18
Nuwellis
NUWE
$160K
– –
0
– –
SCTL
19
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$4.25M 2.22%
+646,700
New +$4.7M
PLX icon
20
Protalix BioTherapeutics
PLX
$191M
$4.18M 2.18%
91,216
-8,784
-9% -$410K
TVRD
21
Tvardi Therapeutics
TVRD
$19.7M
$3.31M 1.73%
+4,946
New +$2.93M
OCRX
22
DELISTED
Ocera Therapeutics, Inc.
OCRX
$3.29M 1.72%
311,821
-215,976
-41% -$3.09M
CYTK icon
23
Cytokinetics
CYTK
$10.5B
$2.99M 1.56%
+315,000
New +$2.85M
CASC
24
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.96M 1.55%
+165,300
New +$2.71M
NSPH
25
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$2.75M 1.44%
64,015
-60,985
-49% -$2.88M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2014 Portfolio in Review

As of Q1 2014, Great Point Partners held 46 positions worth $191M, up 35% from $142M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Great Point Partners deployed $34.4M of net new capital in Q1 2014, opening 18 new positions and adding to 5 existing holdings. Its largest new stake was Tenax Therapeutics: 63 shares worth $11.1M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 44% a quarter earlier.

On the sell side, the largest reduction was FURIEX PHARMACEUTICALS INC COM STK (DE), an estimated $8.78M trimmed.

  • Great Point Partners's largest Q1 2014 buy was Tenax Therapeutics: 63 shares worth $11.1M.
  • Great Point Partners added most to VOLCANO CORPORATION COM STK in Q1 2014, an estimated $2.14M increase.
  • Great Point Partners's biggest Q1 2014 reduction was FURIEX PHARMACEUTICALS INC COM STK (DE), cutting an estimated $8.78M.
  • Great Point Partners fully exited Aerie Pharmaceuticals in Q1 2014, selling an estimated $5.54M.
  • Great Point Partners's ten largest holdings make up 57% of its $191M portfolio in Q1 2014.
  • Great Point Partners opened 18 new positions and closed 10 in Q1 2014.
  • Great Point Partners's portfolio value rose 35% quarter-over-quarter to $191M.

Based on Great Point Partners's 13F filing for Q1 2014, filed 15 May 2014.